A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Acting as GLP-1R agonists (GLP-1RAs), the drugs promote feelings of satiety and fullness, aiding weight loss among patients who are overweight or obese. Aside from their success for type 2 diabetes ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and Wegovy develop complications with their eyesight, highlighting that we ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study. About 65% of those without diabetes ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...